个人简介

中山大学肿瘤学博士，师从于肿瘤学家吴一龙教授，主攻以分子靶向治疗、免疫治疗为主的肺癌多学科综合治疗，对生物标志物指导下的肺癌精准治疗、靶向治疗耐药机制和克服耐药策略研究方面有深入研究，熟练掌握肺癌的最新国际诊疗规范和前沿进展，参加100余项国际、国内多中心临床研究，多次受邀在国内、国际学术会议上进行专题报告。在“2020全国肺癌专家学术影响力排名前100强”中排名第40，是前40名中的6个女性肺癌专家之一。主持国家十三五重点研发计划项目一项，主持国家自然科学基金面上项目四项，广东省自然科学基金两项，广州市珠江科技新星专项、吴阶平医学基金肿瘤专项以及广东省医学科研基金各一项，广东省高水平建设医院登峰计划项目一项。获国家科学技术进步奖二等奖一项，中华医学奖一等奖一项，广东省科技进步一等奖两项、二等奖两项。发表SCI论文124篇，其中第一作者或通讯作者35篇，单篇最高影响因子66.675分，最高他引199次，总计他引2226次，影响因子＞30分总共5篇。作为主译出版译著《抗肿瘤药物I期临床研究实践指南》（34万字）一部，作为编委出版专著《遗传性肿瘤遗传咨询》，于国内核心期刊、报刊发表文章四十余篇，获聘南方医科大学、华南理工大学医学院、汕头大学博士/硕士研究生导师。荣获广东省五一劳动奖章和广东青年五四奖章、全国青年岗位能手、中国肺癌学术翘楚奖、广州市珠江科技新星以及新时期广东省杰出女科技工作者等多项荣誉称号。2017年荣获广东省首批医学领军人才和杰出青年医学人才。

研究领域

肺癌的转化性研究。

个人成果

发表的主要论文：

第一作者/通讯作者（^#第一作者 *通讯作者）

1.Qing Zhou^#, Ming Chen^#, Ou Jiang, Yi Pan, Desheng Hu, Qin Lin, Gang Wu, Jiuwei Cui, Jianhua Chang, Yufeng Cheng, Cheng Huang, Anwen Liu, Nong Yang, Youling Gong, Chuan Zhu, Zhiyong Ma, Jian Fang, Gongyan Chen, Jun Zhao, Anhui Shi, Yingcheng Lin, Guanghui Li, Yunpeng Liu, Dong Wang, Rong Wu, Xinhua Xu, Jianhua Shi, Zhihua Liu, Na Cui, Jingru Wang, Qiang Wang, Ran Zhang, Jason Yang, Yi-Long Wu.Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim resultsof a randomised, double-blind, multicentre, phase 3 trial, The Lancet Oncology,2022, DOI:OI:https://doi.org/10.1016/S1470-2045(21)00630-6 (IF=41.316)

2. Yang L, He YT, Dong S, Wei XW, Chen ZH, Zhang B, Chen WD, Yang XR, Wang F, Shang XM, Zhong WZ, Wu YL, Zhou Q*. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. J Immunother Cancer. 2022 Jan;10(2):e003534. doi: 10.1136/jitc-2021-003534（IF=13.751）

3. Zhou Q^#, Wu L, Hu P, An T, Zhou J, Zhang L, Liu XQ, Luo F, Zheng X, Cheng Y, Yang N, Li J, Feng J, Han B, Song Y, Wang K, Zhang L, Fang J, Zhao H, Shu Y, Lin XY, Chen Z, Gan B, Xu WH, Tang W, Zhang X, Yang JJ, Xu X, Wu YL. A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. Clin Cancer Res. 2021. doi: 10.1158/1078-0432.CCR-21-2595. （IF= 12.531）

4.Cui JW^#, Zhou Q^#, Lu S, Cheng Y, Wang J, Bai RL, Li WQ, Qian L, Chen XY, Fan Y, Huang C, Liu XQ, Tu HY, Yang JJ, Zhang L, Zhou JY, Zhong WZ, Wu YL. The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options. Transl Lung Cancer Res 2021;10(8):3594-3607. （IF= 6.498）

5. Zhou Q^#, Xu CR^#, Cheng Y, Liu YP, Chen GY, Cui JW, Yang N, Song Y, Li XL, Lu S, Zhou JY, Ma ZY, Yu SY, Huang C, Shu YQ, Wang Z, Yang JJ, Tu HY, Zhong WZ, Wu YL^*. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 2021: S1535-6108(21)00382-2. （IF= 31.744）

6. Yang L., He Y., Kang J., Zheng M., Chen Z., Yan H., Zhang X., Yang J., Wu Y., Zhou Q*. Clinical features and intervention timing in patients with pregnancy-associated non-small-cell lung cancer. J Thorac Dis, 13(7): 4125-4136.（IF= 2.895）

7. Lu C, Zhou Q*. Diagnostics, therapeutics and RET inhibitor resistance for RET fusion-positive non-small cell lung cancers and future perspectives. Cancer Treat Rev. 2021; 96: 102153. （IF= 12.111）

8. Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, Zhao S, Dong X, Yao M, Wang K, Zhou Q*. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Med. 2021; doi: 10.1002/cam4.3649. （IF= 4.452）

9. Zhou Q, Chen M, Wu G, Chang JH, Jiang O, Cui JW, Han G, Lin Q, Fang J, Chen GY, Wu YL. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020; 9(5):2008-2015. (IF= 6.498)

10. Yang XR, Pi C, Yu R, Fan XJ, Peng XX, Zhang XC, Chen ZH, Wu X, Shao Y, Wu YL, Zhou Q*. Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer. Clin Exp Metastasis. 2020. doi: 10.1007/s10585-020-10062-y. (IF= 5.150)

11. Wang F, Wang S, Zhou Q*. The Resistance Mechanisms of Lung Cancer Immunotherapy. Front Oncol. 2020; 10:568059. (IF= 6.244)

12. Peng XX, Yu RY, Wu X, Wu SY, Pi C, Chen ZH, Zhang XC, Gao CY, Shao YW, Liu L, Wu YL, Zhou Q*. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer. J Immunother Cancer. 2020; 8(1). pii: e000376. (IF= 13.751)

13. Guo LH, Zhang MF, Zhang HL, Zhou JY, Cai XH, Long Y, Guo QS, Yang N, Zhao J, Xie ZH, Jiang B, Zhu Y, Fan Y, Xie CY, Hu Y, Yao Y, Jia J, Li XL, Cui JW, Sui XZ, Lin W, Cheng Y, Wang HJ, Wang CL, Zhao MF, Qiao GB, Peng LJ, Yang L, Chen GY, Cai KC, Xu XH, Zhang LM, Feng GS, Zhou JM, Wu GW, Dong XR, Wang LF, Zhang HM, Gao YJ, Jiang QY, Cang SD, Yang ZX, Song X, Liu XQ, Zhu B, Chen FX, Hu CH, Chen X, Wu YL*, Zhou Q*. Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients with Advanced Lung Adenocarcinoma. Front Oncol. 2020; 10:1568.（IF= 6.244）

14. Gao X, Wei XW, Zheng MY, Chen ZH, Zhang XC, Zhong WZ, Yang JJ, Wu YL, Zhou Q*. Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. J Thorac Dis. 2020 Oct;12(10):5822-5832.（IF= 2.895）

15. Wei XW, Gao X, Zhang XC, Yang JJ, Chen ZH, Wu YL, Zhou Q*. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. Thorac Cancer. 2020;11(6):1512-1521. (IF= 3.500)

16. Zhang YC, Chen ZH, Zhang XC, Xu CR, Yan HH, Xie Z, Chuai SK, Ye JY, Han-Zhang H, Zhang Z, Bai XY, Su J, Gan B, Yang JJ, Li WF, Tang W, Luo FR, Xu X, Wu YL*, Zhou Q*. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. EBioMedicine. 2019; 43:180-187. (IF= 8.143)

17. Guo L, Chen Z, Xu C, Zhang X, Yan H, Su J, Yang J, Xie Z, Guo W, Li F, Wu YL*, Zhou Q*. Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level. BMC Cancer. 2019;19(1):369. (IF= 4.430)

18. Zhou Q, Wu YL, Corral J, Nakagawa K, Garon EB, Sbar EI, Wang T, Sandin R, Noonan K, Gernhardt D, Mok TS. Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. Future Oncol. 2019;15(13):1481-1491. (IF= 3.404)

19. Peng XX, Yan LX, Liu C, Wang SY, Li WF, Gao X, Wei XW, Zhou Q*. Benign disease prone to be misdiagnosed as malignant pulmonary nodules: Minute meningothelioid nodules. Thorac Cancer. 2019;10(5):1182-1187. (IF= 3.500)

20. Zhang YC^#, Zhou Q^#, Chen ZH, Zhang MF, Yang JJ, Tu HY, Zhang XC, Xu CR, Yan HH, Peng XX, Bai XY, Chuai SK, Ye JY, Wu YL.The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer:opportunities for third-generation EGFR inhibitors re-challenge. Science Bulletin. 2019; 64(08):499-503. (IF= 11.780)

21. Pi C, Xu CR, Zhang MF, Peng XX, Wei XW, Gao X, Yan HH, Zhou Q*. EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. Thorac Cancer. 2018. doi: 10.1111/1759-7714.12651. (IF= 3.500)

22. Zhou Q, Chen XY, Yang ZM, Wu YL. The changing landscape of clinical trial and approval processes in China. Nat Rev Clin Oncol. 2017;14(9):577-583. (IF= 66.675)

23. Ke EE^#, Zhou Q^#, Zhang QY, Su J, Chen ZH, Zhang XC, Xu CR, Yang JJ, Tu HY, Yan HH, Zhang YC, Niu FY, Wu YL*. A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. J Thorac Oncol. 2017;12(9):1368-1375. (IF= 15.609)

24. Zhou Q, Song Y, Zhang X, Chen GY, Zhong DS, Yu Z, Yu P, Zhang YP, Chen JH, Hu Y, Feng GS, Song X, Shi Q, Yang LL, Zhang PH, Wu YL*. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). BMC Cancer. 2017;17(1):462. (IF=4.430)

25. Zhang Q, Ke E, Niu F, Deng W, Chen Z, Xu C, Zhang X, Zhao N, Su J, Yang J, Yan H, Wu YL*, Zhou Q*. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma. Oncotarget. 2017;8(3):4994-5002.

26. Pi C, Zhang MF, Peng XX, Zhang YC, Xu CR, Zhou Q*. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine? Expert Rev Mol Diagn. 2017;17(12):1089-1096. (IF= 5.225)

27. Zhou Q^#, Yang JJ^#, Chen ZH^#, Zhang XC, Yan HH, Xu CR, Su J, Chen HJ, Tu HY, Zhong WZ, Yang XN, Wu YL*. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. J Hematol Oncol. 2016;9(1):86. (IF= 17.388)

28. Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL*, Zhou Q*. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Thorac Cancer. 2016;7(6):648-654. (IF= 3.500)

29. Zhou Q, Wu YL. Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value. Journal of Global Oncology. 2016; 3(4):285-288.

30. Zhou Q, Cheng Y, Yang JJ, Zhao MF, Zhang L, Zhang XC, Chen ZH, Yan HH, Song Y, Chen JH, Feng WN, Xu CR, Wang Z, Chen HJ, Zhong WZ, Liu YP, Wu YL. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Ann Oncol. 2014;25(12):2385-91. (IF= 32.976)

31. Zhou Q, Zhou CC, Chen GY, Cheng Y, Huang C, Zhang L, Xu CR, Li AW, Yan HH, Su J, Zhang XC, Yang JJ, Wu YL. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). Lung Cancer. 2014;83(3):369-73. (IF= 5.705)

32. Zhou Q^#, Zhang XC^#, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL*. Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2011;29(24):3316-21. (IF= 44.544)

33. Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR#. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs. 2011;29(2):340-6. (IF= 3.850)

34. Zhou Q, Guo AL, Xu CR, An SJ, Wang Z, Yang SQ, Wu YL#. A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. Clin Exp Immunol. 2008;153(3):392-400. (IF= 4.330)